Artificial Intelligence
Rapid National Growth Drives Expansion of Healthmap Solutions Executive Leadership Team with Eric Reimer Appointed Chief Executive Officer
TAMPA, Fla., Oct. 01, 2020 (GLOBE NEWSWIRE) — Healthmap Solutions (Healthmap), a growing specialty Population Health Management (PHM) company with an industry-leading Kidney Health Management (KHM) program, today announced an expansion of the company’s executive leadership team in response to a year of unprecedented growth. Eric Reimer, an Operating Partner at private equity firm Water Street, current Chairman at Unified Women’s Healthcare and ELAP Solutions, former Chief Executive Officer of CareCentrix, and current co-Chairman of the Healthmap Board of Directors, has been appointed Chief Executive Officer. Joe Vattamattam, a Co-founder of Healthmap, will become President & Chief Financial Officer responsible for leading the organization to align its innovative product offerings with its value proposition, culminating in high performing risk-bearing programs. Andrew Wall, a Co-founder of the company, will assume the new role of Chief Innovation Officer, leading a team to drive product strategy and address new market opportunities. All three executives will continue to serve on the Board of Directors in their current positions.
“This is a watershed moment for specialty population health management and kidney health management specifically. Kidney disease is a pervasive and under-diagnosed condition, and addressing racial disparities in healthcare, especially severe for kidney disease, has rightfully become an important priority. Regulatory changes are spurring much-needed innovation, with the 21st Century Cures Act opening the door to more affordable kidney care and a wider array of benefits for thousands of people,” said Eric Reimer, Healthmap’s new Chief Executive Officer. “This convergence of events is shining a light on one of the most significant challenges facing healthcare: improving care, outcomes, experience, and costs for one of our most vulnerable and costly populations. Healthmap Solutions is uniquely ready to scale to meet these challenges head-on, and our capabilities are a differentiator. I’m excited to join the company at this important time.”
Healthmap has stepped into a leadership role within this new market dynamic. In May, the company entered into an agreement with a leading national health plan to provide KHM services for the company’s Medicare Advantage and Commercial health plan members living with kidney disease in Florida. A month later, Healthmap partnered with a large Blues health plan in the western U.S. to provide KHM services. Healthmap is in late-stage contracting with several leading health plans to implement its KHM services, amounting to tens of thousands of patients across the country. Currently, the company supports the health of 4 million lives and manages $1 billion in medical spend.
“Explosive growth in the kidney health management sector has accelerated the need for the life-altering work we do for kidney patients, and for the providers and health plans that support and care for them,” said Joe Vattamattam, President & Chief Financial Officer at Healthmap Solutions. “Eric’s successes in catapulting companies to the next level, in-depth understanding of our sector, and passion for our mission makes him an invaluable addition to our executive team. I am thrilled he is formally joining Healthmap and look forward to working with him at this exciting time for our company and the industry.”
Kidney health management is a burgeoning sector of the healthcare industry. In the U.S. more than 37 million people live with chronic kidney disease, and close to 800,000 have end-stage renal disease (ESRD), the more serious disease state which requires dialysis or a kidney transplant to survive. In 2017, Medicare alone spent a total of $120 billion on kidney care, an increase of $6 billion since 2016. Regulatory changes encouraging increased adoption of in-home dialysis and modernization of the transplant pipeline are accelerating transformation in kidney care. And starting this fall, the 21st Century Cures Act will open the door to thousands of previously ineligible ESRD patients to enroll in a Medicare Advantage (M.A.) plan with coverage effective January 1, 2021. The Centers for Medicare and Medicaid Services (CMS) projects that 63% of newly eligible ESRD patients will choose coverage under an MA plan by 2026, bringing significant costs. While only 1% of Medicare beneficiaries have ESRD, they represent 7% of Medicare spending, and an average medical loss ratio for an ESRD beneficiary is 112%.
“Innovative payment models for kidney care allowed for adoption of new technical and clinical innovations that improve care and better manage costs,” said Andrew Wall, Chief Innovation Officer. “By harnessing the best ideas, incubating new capabilities, and collaborating with our valued business partners, I am confident we can significantly improve the quality of life for those living with kidney disease. Over the coming year, enhancements to our population health models, AI, telemedicine, and data liquidity will increase choice and improve quality of life for kidney patients, encourage in-home dialysis, slow the progression of conditions, optimize patient activation, and overcome Social Determinant of Health barriers. I couldn’t be more excited to be at the forefront of our industry-leading efforts.”
Healthmap Solutions is a leading national provider of kidney population health management services. The company’s kidney health management expertise uses the powerful and proven combination of big data, artificial intelligence, machine learning, and predictive analytics to identify people living with CKD. This technology is integrated with superior clinical expertise to empower healthcare providers with actionable, data-driven, and clinically-proven insights and patient-centered care recommendations. The company’s multidisciplinary Care Navigation team collaborates with the patient’s healthcare providers and specialists to coordinate care and recommend medication modifications as warranted. The Care Navigation team connects with patients to provide the support and information needed for them to be empowered and engaged in their healthcare. The program results are measured and reported compared to value-based, quality, and outcome metrics, and modifications to care and treatment plans are made to optimize quality outcomes for each patient and best manage costs.
About Healthmap Solutions
Healthmap Solutions is a specialty population health management company with a specific Kidney Health Management (KHM) solution for kidney disease patients. The company serves health plans, accountable care organizations (ACOs), and provider groups seeking value-based solutions that improve the clinical care and financial performance of high-risk, high-cost kidney patient populations. The company has a rich history forged in data and analytics, having begun as a healthcare data clearinghouse, and later adding robust health analytics expertise. Today, Healthmap Solutions uses that experience to power a complex KHM program with its clinical experts. Healthmap Solutions also provides similar integrated programs across a full range of specialty population health management. For more information: healthmapsolutions.com
Contact:
Chris Cooney
The WilMark Group
407-921-6932
[email protected]
Artificial Intelligence
Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times
Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.
“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html
Artificial Intelligence
Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data
ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html
Artificial Intelligence
Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe
Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.
As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html
-
Uncategorized7 days ago
Artificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence5 days ago
Japan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized6 days ago
Google to roll out AI-generated summaries at top of search engine
-
Uncategorized4 days ago
Coca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence5 days ago
Strava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence5 days ago
Data Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Artificial Intelligence4 days ago
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days ago
IBM Expands Qiskit, World’s Most Performant Quantum Software